Vanda Pharmaceuticals INC 10-Q quarterly reports

Vanda Pharmaceuticals Inc. filed its Q2 2026 Form 10-Q, detailing a net loss of $62.5 million, a decrease in HETLIOZ sales, and ongoing litigation, while also highlighting growth in Fanapt and progress in regulatory reviews for other products.

Vanda Pharmaceuticals reported a 3% increase in total revenues for Q1 2026, driven by strong Fanapt sales, while net loss widened due to increased SG&A expenses and lower R&D spending.

Vanda Pharmaceuticals reported a significantly wider net loss in the third quarter of 2025, driven by increased R&D and commercialization expenses, despite strong Fanapt sales growth.

Vanda Pharmaceuticals Inc. reported a significant increase in net loss for the second quarter and first half of 2025, driven by higher research and development and selling, general, and administrative expenses, despite growth in Fanapt sales.

Vanda Pharmaceuticals announces its Q1 2025 financial results, showcasing increased revenue and significant growth in Fanapt prescriptions, while navigating generic competition for Hetlioz and advancing its pipeline.

Vanda Pharmaceuticals' Q3 2024 results show a revenue increase driven by the launch of Fanapt for bipolar disorder and PONVORY for multiple sclerosis, despite ongoing challenges with HETLIOZ generic competition.

Vanda Pharmaceuticals' Q2 2024 results show a complex picture with increased revenues offset by higher expenses and ongoing legal challenges.

Vanda Pharmaceuticals' Q1 2024 revenue decreased by 24% year-over-year, primarily due to a decline in HETLIOZ sales, while the company continues to advance its pipeline and commercialize new products.